Table 2.
Discontinued PD treatments by patient age. Percentages are computed out of the total number of Italy evaluable patients for the FAS by patient age
| Categories | Active | Patients aged < 75 yrs (N = 452) |
Patients aged > 75 yrs (N = 137) |
FAS (N = 589) |
|---|---|---|---|---|
| At least one | Any | 81 (17.9%) | 17 (12.4%) | 98 (16.6%) |
| COMT inhibitors | Any | 5 (1.1%) | 0.0 | 5 (0.8%) |
| Carbidopa—Entacapone—Levodopa | 5 (1.1%) | 0.0 | 5 (0.8%) | |
| DA | Any | 1 (0.2%) | 0.0 | 1 (0.2%) |
| Pramipexole dihydrochloride | 1 (0.2%) | 0.0 | 1 (0.2%) | |
| Levodopa | Any | 11 (2.4%) | 1 (0.7%) | 12 (2.0%) |
| Benserazide hydrochloride—Levodopa | 3 (0.7%) | 1 (0.7%) | 4 (0.7%) | |
| Carbidopa—Levodopa | 2 (0.4%) | 0.0 | 2 (0.3%) | |
| Carbidopa—Melevodopa | 2 (0.4%) | 0.0 | 2 (0.3%) | |
| Carbidopa—Entacapone—Levodopa | 5 (1.1%) | 0.0 | 5 (0.8%) | |
| MAO inhibitors | Any | 73 (16.2%) | 16 (11.7%) | 89 (15.1%) |
| Rasagiline | 3 (0.7%) | 1 (0.7%) | 4 (0.7%) | |
| Rasagiline mesylate | 46 (10.2%) | 12 (8.8%) | 58 (9.8%) | |
| Rasagiline tartrate | 1 (0.2%) | 0.0 | 1 (0.2%) | |
| Selegiline hydrochloride | 23 (5.1%) | 3 (2.2%) | 26 (4.4%) |
A patient could have more than one previous and terminated PD treatments. Carbidopa-Entacapone-Levodopa is shown both as Levodopa and as COMT inhibitors. COMT Catechol-O-methyltransferase; DA Dopamine agonists; MAO monoamine oxidase; FAS Full analysis Set